How is AI advancing drug discovery for rare diseases?

AI platforms ingest biological, chemical, and clinical data to generate hypotheses about disease targets and candidate molecules, significantly speeding up the discovery and repurposing of treatments for rare and neglected disorders.

What is GenEditBio's approach to gene editing with AI?

GenEditBio uses AI to refine engineered protein delivery vehicles (ePDVs) for precise in vivo gene editing, aiming for one-time injections directly into affected tissues to make therapies more scalable and accessible.

What future applications of AI are anticipated in biotech?

Future applications include building digital twins of humans to conduct virtual clinical trials, which could help accelerate the approval of new therapies and lead to more personalized patient treatments.

Home / Science / AI Fuels Biotech Leap: New Cures on Horizon

AI Fuels Biotech Leap: New Cures on Horizon

6 Feb

•

Summary

AI accelerates drug discovery and gene editing for rare diseases.
Companies use AI to find drug targets and design delivery vehicles.
AI's role is expanding to virtual trials and personalized medicine.

AI Fuels Biotech Leap: New Cures on Horizon

Modern biotechnology is harnessing artificial intelligence to overcome long-standing challenges in drug discovery and gene editing, particularly for rare diseases. Companies are employing AI to enhance productivity and address talent shortages in the pharmaceutical sector.

Insilico Medicine utilizes its AI platform to ingest diverse data, generate hypotheses for disease targets, and identify potential drug candidates. This approach significantly reduces the time and cost associated with discovering and repurposing therapies, as seen in their work on ALS treatments.

GenEditBio is advancing in vivo gene editing with AI-driven delivery vehicles. Their proprietary ePDV technology, refined through machine learning, aims for precise, one-time injections of gene-editing tools directly into affected tissues, making treatments more affordable and globally accessible. The company is pursuing FDA trials for corneal dystrophy.